SAN DIEGO, Dec. 6, 2016 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH), the world's largest professional society concerned with the causes and treatment of blood disorders, will highlight the following novel studies in its late-breaking abstracts session today at the 58th ASH Annual Meeting and Exposition in San Diego:
- Additions to Standard Multiple Myeloma Therapy Do Not Appear to Yield Additional Benefit
- IKZF1 Gene Mutations Found to Increase Hereditary Risk for Acute Lymphocytic Leukemia in Children
- Cancer Drug Ibrutinib Found Helpful in Treating Graft Versus Host Disease After Stem Cell Transplant
- New Data Shed Light on Potential Advantages of Pacritinib for Patients with Myelofibrosis
- First Multicenter Trial Finds CAR T-Cell Immunotherapy Effective, Feasible for Hard-to-Treat Lymphoma
For the complete annual meeting program and abstracts, visit www.hematology.org/annual-meeting or download ASH's annual meeting mobile app. Up-to-the-minute meeting information can also be found by following ASH on Twitter (@ASH_hematology) and the meeting hashtag #ASH16.
The American Society of Hematology (ASH) (www.hematology.org) is the world's largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The Society publishes Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, as well as the newly launched, online, open-access journal, Blood Advances (www.bloodadvances.org).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/highly-anticipated-late-breaking-abstracts-session-to-feature-groundbreaking-scientific-data-during-58th-ash-annual-meeting-300373294.html
SOURCE American Society of Hematology